FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Res Commun / Cell therapy for tendinitis, experimental and clinical repor...
Veterinary research communications2008; 32 Suppl 1; S33-S38; doi: 10.1007/s11259-008-9085-3

Cell therapy for tendinitis, experimental and clinical report.

Abstract: To compare cultured bone marrow mesenchymal cells (cBMSC), bone marrow mononucleated cells (BMMNCs), and placebo to repair collagenase-induced tissue damage in an equine model of experimental tendonitis, 6 Standardbred horses with no signs of previous SDF tendon injury have been recruited. Three weeks after collagenase treatment an average of either 5.5 x 10(6) cBMSCs or 122.3 x 10(6) BMMNCs, saline solution (placebo) or fibrin glue were injected intralesionally in random order. Horses were stall rested for 21 weeks, and tendon ultrasound scans performed before and during this period. Horses were euthanized and tendons harvested for histology and immunohistochemistry. Data observed in this study showed effectiveness of cBMSC and BMMNC in regenerating tendon tissue after collagenase -induced tendonitis. Both cBMSC and BMMNC transplantation resulted in qualitatively similar regeneration of tendon extracellular matrix in terms of type I/III collagen ratio, fiber orientation, and COMP expression. After this favourable results, 20 horses were recruited referred for spontaneous lesions of the flexor tendons or the suspensory ligament. Horses were treated with autologous graft of BMMNCs.After treatment the. the exercise program allowed was 8 weeks stall rest, 4 weeks hand walking, 4 weeks trotting, 4 weeks of gradually raising of exercise level then horses were gone back to race. US characteristics of lesions started to improve at T3. CSA-l, FPS and TLS were better in all patients, with an appreciable filling of lesions indicated by a decreasing of CSA-l and increasing of TLS. When horses started the exercise program T8 tendon architecture improved, demonstrated by their longitudinal alignment and length. At T6, and persistently in later follow-up, no lameness was evident by clinical examination. At time of writing 12 patients (60%) were go back to races, while other 8 (40%) are under controlled exercise program. Re-injury rate was assessed at 25%. All the owners judged good to excellent the outcome in term of athletic success.
Get Full Text
Publication Date: 2008-08-08 PubMed ID: 18686004DOI: 10.1007/s11259-008-9085-3Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research studied the effectiveness of using cultured bone marrow mesenchymal cells (cBMSC) and bone marrow mononucleated cells (BMMNCs) in treating tendinitis in horses. The results showed promising regeneration of damaged tendon tissue and a significant number of the studied horses were able to return to racing after treatment.

Overview of the Study

  • This study aimed to compare the effectiveness of cultured bone marrow mesenchymal cells (cBMSC), bone marrow mononucleated cells (BMMNCs), and a saline solution (placebo) in repairing collagenase-induced tissue damage in an equine experimental tendonitis model.
  • Throughout the research, ultrasound scans were carried out before and after treatment to monitor the condition of the tendons in the different groups of horses.

Experimental Observations

  • The results demonstrated the effectiveness of both cBMSC and BMMNC in regenerating tendon tissue after induced tendonitis.
  • The regeneration of the tendon extracellular matrix was seen to be qualitatively similar in terms of type I/III collagen ratio, fiber orientation, and COMP expression.

Treatment and Results of Clinical Cases

  • After the positive results from the experimental study, the treatment was applied to 20 horses suffering from spontaneous lesions of the flexor tendons or the suspensory ligament.
  • Changes in ultrasound characteristics of lesions were recorded, improvements were observed in all patients.
  • Signs of regenerated tendon architecture were evident at the time the horses began their exercise programme.
  • At the time of writing, 12 of the horses (60%) had returned to races, while the remaining 8 (40%) were under a controlled exercise programme.
  • The rate of re-injury was recorded to be 25%, and all the owners reported favorable outcomes in terms of athletic success.

Conclusions

  • The study concluded that cell therapy using bone marrow mesenchymal cells and bone marrow mononucleated cells can effectively repair damaged tissue in tendonitis. The treatment method has resulted in successful athletic recovery for a majority of the treated horses, thus indicating its potential application in treating tendon injuries in equine veterinary practice.

Cite This Article

APA
Lacitignola L, Crovace A, Rossi G, Francioso E. (2008). Cell therapy for tendinitis, experimental and clinical report. Vet Res Commun, 32 Suppl 1, S33-S38. https://doi.org/10.1007/s11259-008-9085-3

Publication

Veterinary research communications
ISSN: 1573-7446
NlmUniqueID: 8100520
Country: Switzerland
Language: English
Volume: 32 Suppl 1
Pages: S33-S38

Researcher Affiliations

Lacitignola, L
  • Dipartimento Scienze Cliniche Veterinarie, Teramo, Italy.
Crovace, A
    Rossi, G
      Francioso, E

        MeSH Terms

        • Animals
        • Bone Marrow Transplantation / veterinary
        • Cell- and Tissue-Based Therapy / methods
        • Cell- and Tissue-Based Therapy / veterinary
        • Fibrin Tissue Adhesive / therapeutic use
        • Horse Diseases / surgery
        • Horse Diseases / therapy
        • Horses
        • Humans
        • Mesenchymal Stem Cell Transplantation / methods
        • Mesenchymal Stem Cell Transplantation / veterinary
        • Sheep
        • Sheep Diseases / surgery
        • Sheep Diseases / therapy
        • Tendinopathy / surgery
        • Tendinopathy / therapy
        • Tendinopathy / veterinary
        • Treatment Outcome

        References

        This article includes 18 references
        1. Dowling BA, Dart AJ, Hodgson DR, Smith RK. Superficial digital flexor tendonitis in the horse.. Equine Vet J 2000 Sep;32(5):369-78.
          pubmed: 11037257doi: 10.2746/042516400777591138google scholar: lookup
        2. Smith RK, Korda M, Blunn GW, Goodship AE. Isolation and implantation of autologous equine mesenchymal stem cells from bone marrow into the superficial digital flexor tendon as a potential novel treatment.. Equine Vet J 2003 Jan;35(1):99-102.
          pubmed: 12553472doi: 10.2746/042516403775467388google scholar: lookup
        3. Awad HA, Butler DL, Boivin GP, Smith FN, Malaviya P, Huibregtse B, Caplan AI. Autologous mesenchymal stem cell-mediated repair of tendon.. Tissue Eng 1999 Jun;5(3):267-77.
          pubmed: 10434073doi: 10.1089/ten.1999.5.267google scholar: lookup
        4. Young RG, Butler DL, Weber W, Caplan AI, Gordon SL, Fink DJ. Use of mesenchymal stem cells in a collagen matrix for Achilles tendon repair.. J Orthop Res 1998 Jul;16(4):406-13.
          pubmed: 9747780doi: 10.1002/jor.1100160403google scholar: lookup
        5. Bianchi G, Muraglia A, Daga A, Corte G, Cancedda R, Quarto R. Microenvironment and stem properties of bone marrow-derived mesenchymal cells.. Wound Repair Regen 2001 Nov-Dec;9(6):460-6.
          pubmed: 11896988doi: 10.1046/j.1524-475x.2001.00460.xgoogle scholar: lookup
        6. Ryu JH, Kim IK, Cho SW, Cho MC, Hwang KK, Piao H, Piao S, Lim SH, Hong YS, Choi CY, Yoo KJ, Kim BS. Implantation of bone marrow mononuclear cells using injectable fibrin matrix enhances neovascularization in infarcted myocardium.. Biomaterials 2005 Jan;26(3):319-26.
          pubmed: 15262474doi: 10.1016/j.biomaterials.2004.02.058google scholar: lookup
        7. Bianchi G, Banfi A, Mastrogiacomo M, Notaro R, Luzzatto L, Cancedda R, Quarto R. Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2.. Exp Cell Res 2003 Jul 1;287(1):98-105.
          pubmed: 12799186doi: 10.1016/s0014-4827(03)00138-1google scholar: lookup
        8. Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation.. Lancet 2003 Jan 4;361(9351):47-9.
          pubmed: 12517468doi: 10.1016/S0140-6736(03)12111-3google scholar: lookup
        9. Sharma P, Maffulli N. Tendon injury and tendinopathy: healing and repair.. J Bone Joint Surg Am 2005 Jan;87(1):187-202.
          pubmed: 15634833doi: 10.2106/JBJS.D.01850google scholar: lookup
        10. Blatt A, Cotter G, Leitman M, Krakover R, Kaluski E, Milo-Cotter O, Resnick IB, Samuel S, Gozal D, Vered Z, Slavin S, Shapira MY. Intracoronary administration of autologous bone marrow mononuclear cells after induction of short ischemia is safe and may improve hibernation and ischemia in patients with ischemic cardiomyopathy.. Am Heart J 2005 Nov;150(5):986.
          pubmed: 16290982doi: 10.1016/j.ahj.2005.07.021google scholar: lookup
        11. Awad HA, Boivin GP, Dressler MR, Smith FN, Young RG, Butler DL. Repair of patellar tendon injuries using a cell-collagen composite.. J Orthop Res 2003 May;21(3):420-31.
          pubmed: 12706014doi: 10.1016/S0736-0266(02)00163-8google scholar: lookup
        12. Cho SW, Park HJ, Ryu JH, Kim SH, Kim YH, Choi CY, Lee MJ, Kim JS, Jang IS, Kim DI, Kim BS. Vascular patches tissue-engineered with autologous bone marrow-derived cells and decellularized tissue matrices.. Biomaterials 2005 May;26(14):1915-24.
          pubmed: 15576165doi: 10.1016/j.biomaterials.2004.06.018google scholar: lookup
        13. Hisatome T, Yasunaga Y, Yanada S, Tabata Y, Ikada Y, Ochi M. Neovascularization and bone regeneration by implantation of autologous bone marrow mononuclear cells.. Biomaterials 2005 Aug;26(22):4550-6.
          pubmed: 15722124doi: 10.1016/j.biomaterials.2004.11.032google scholar: lookup
        14. Smith RK, Webbon PM. Harnessing the stem cell for the treatment of tendon injuries: heralding a new dawn?. Br J Sports Med 2005 Sep;39(9):582-4.
          pubmed: 16118291doi: 10.1136/bjsm.2005.015834google scholar: lookup
        15. Hankemeier S, Keus M, Zeichen J, Jagodzinski M, Barkhausen T, Bosch U, Krettek C, Van Griensven M. Modulation of proliferation and differentiation of human bone marrow stromal cells by fibroblast growth factor 2: potential implications for tissue engineering of tendons and ligaments.. Tissue Eng 2005 Jan-Feb;11(1-2):41-9.
          pubmed: 15738660doi: 10.1089/ten.2005.11.41google scholar: lookup
        16. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial.. Lancet 2002 Aug 10;360(9331):427-35.
          pubmed: 12241713doi: 10.1016/S0140-6736(02)09670-8google scholar: lookup
        17. Cancedda R, Bianchi G, Derubeis A, Quarto R. Cell therapy for bone disease: a review of current status.. Stem Cells 2003;21(5):610-9.
          pubmed: 12968115doi: 10.1634/stemcells.21-5-610google scholar: lookup
        18. Banfi A, Muraglia A, Dozin B, Mastrogiacomo M, Cancedda R, Quarto R. Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy.. Exp Hematol 2000 Jun;28(6):707-15.
          pubmed: 10880757doi: 10.1016/s0301-472x(00)00160-0google scholar: lookup

        Citations

        This article has been cited 18 times.
        1. Quintero D, Perucca Orfei C, Kaplan LD, de Girolamo L, Best TM, Kouroupis D. The roles and therapeutic potentialof mesenchymal stem/stromal cells and their extracellular vesicles in tendinopathies.. Front Bioeng Biotechnol 2023;11:1040762.
          doi: 10.3389/fbioe.2023.1040762pubmed: 36741745google scholar: lookup
        2. Maleas G, Mageed M. Effectiveness of Platelet-Rich Plasma and Bone Marrow Aspirate Concentrate as Treatments for Chronic Hindlimb Proximal Suspensory Desmopathy.. Front Vet Sci 2021;8:678453.
          doi: 10.3389/fvets.2021.678453pubmed: 34222402google scholar: lookup
        3. Ribitsch I, Baptista PM, Lange-Consiglio A, Melotti L, Patruno M, Jenner F, Schnabl-Feichter E, Dutton LC, Connolly DJ, van Steenbeek FG, Dudhia J, Penning LC. Large Animal Models in Regenerative Medicine and Tissue Engineering: To Do or Not to Do.. Front Bioeng Biotechnol 2020;8:972.
          doi: 10.3389/fbioe.2020.00972pubmed: 32903631google scholar: lookup
        4. Lui PPY. Mesenchymal Stem Cell-Derived Extracellular Vesicles for the Promotion of Tendon Repair - an Update of Literature.. Stem Cell Rev Rep 2021 Apr;17(2):379-389.
          doi: 10.1007/s12015-020-10023-8pubmed: 32785869google scholar: lookup
        5. Kamm JL, Parlane NA, Riley CB, Gee EK, Dittmer KE, McIlwraith CW. Blood type and breed-associated differences in cell marker expression on equine bone marrow-derived mesenchymal stem cells including major histocompatibility complex class II antigen expression.. PLoS One 2019;14(11):e0225161.
          doi: 10.1371/journal.pone.0225161pubmed: 31747418google scholar: lookup
        6. Gibson MA, Brown SG, Brown NO. Semitendinosus myopathy and treatment with adipose-derived stem cells in working German shepherd police dogs.. Can Vet J 2017 Mar;58(3):241-246.
          pubmed: 28246410
        7. Kong X, Ni M, Zhang G, Chai W, Li X, Li Y, Wang Y. [Application of tendon-derived stem cells and bone marrow-derived mesenchymal stem cells for tendon injury repair in rat model].. Zhejiang Da Xue Xue Bao Yi Xue Ban 2016 Mar;45(2):112-9.
          doi: 10.3785/j.issn.1008-9292.2016.03.02pubmed: 27273983google scholar: lookup
        8. Sun HB, Schaniel C, Leong DJ, Wang JH. Biology and mechano-response of tendon cells: Progress overview and perspectives.. J Orthop Res 2015 Jun;33(6):785-92.
          doi: 10.1002/jor.22885pubmed: 25728946google scholar: lookup
        9. Ho JO, Sawadkar P, Mudera V. A review on the use of cell therapy in the treatment of tendon disease and injuries.. J Tissue Eng 2014;5:2041731414549678.
          doi: 10.1177/2041731414549678pubmed: 25383170google scholar: lookup
        10. MacLean S, Khan WS, Malik AA, Snow M, Anand S. Tendon regeneration and repair with stem cells.. Stem Cells Int 2012;2012:316281.
          doi: 10.1155/2012/316281pubmed: 25098364google scholar: lookup
        11. Carvalho Ade M, Badial PR, Álvarez LE, Yamada AL, Borges AS, Deffune E, Hussni CA, Garcia Alves AL. Equine tendonitis therapy using mesenchymal stem cells and platelet concentrates: a randomized controlled trial.. Stem Cell Res Ther 2013 Jul 22;4(4):85.
          doi: 10.1186/scrt236pubmed: 23876512google scholar: lookup
        12. Ruzzini L, Longo UG, Rizzello G, Denaro V. Stem cells and tendinopathy: state of the art from the basic science to clinic application.. Muscles Ligaments Tendons J 2012 Jul;2(3):235-8.
          pubmed: 23738302
        13. Tetta C, Consiglio AL, Bruno S, Tetta E, Gatti E, Dobreva M, Cremonesi F, Camussi G. The role of microvesicles derived from mesenchymal stem cells in tissue regeneration; a dream for tendon repair?. Muscles Ligaments Tendons J 2012 Jul;2(3):212-21.
          pubmed: 23738299
        14. Spaas JH, Guest DJ, Van de Walle GR. Tendon regeneration in human and equine athletes: Ubi Sumus-Quo Vadimus (where are we and where are we going to)?. Sports Med 2012 Oct 1;42(10):871-90.
          doi: 10.1007/BF03262300pubmed: 22963225google scholar: lookup
        15. Young M. Stem cell applications in tendon disorders: a clinical perspective.. Stem Cells Int 2012;2012:637836.
          doi: 10.1155/2012/637836pubmed: 22448174google scholar: lookup
        16. Schwarz C, Leicht U, Drosse I, Ulrich V, Luibl V, Schieker M, Röcken M. Characterization of adipose-derived equine and canine mesenchymal stem cells after incubation in agarose-hydrogel.. Vet Res Commun 2011 Dec;35(8):487-99.
          doi: 10.1007/s11259-011-9492-8pubmed: 21755422google scholar: lookup
        17. Torricelli P, Fini M, Filardo G, Tschon M, Pischedda M, Pacorini A, Kon E, Giardino R. Regenerative medicine for the treatment of musculoskeletal overuse injuries in competition horses.. Int Orthop 2011 Oct;35(10):1569-76.
          doi: 10.1007/s00264-011-1237-3pubmed: 21394594google scholar: lookup
        18. Watts AE, Yeager AE, Kopyov OV, Nixon AJ. Fetal derived embryonic-like stem cells improve healing in a large animal flexor tendonitis model.. Stem Cell Res Ther 2011 Jan 27;2(1):4.
          doi: 10.1186/scrt45pubmed: 21272343google scholar: lookup
        Subscribe to our newsletter
        Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.